Drugs for cancer, arthritis and HIV on Medicare’s list for 2028 price cuts

Still, the medications in the latest round of negotiations — which now includes “Part B” drugs given in doctors offices — draw very limited revenue from Medicare, an analyst pointed out.

By Jonathan Gardner • Jan. 28, 2026

Express Scripts considering settlement in FTC insulin price lawsuit

The antitrust agency paused its lawsuit against the pharmacy benefit manager while the two discuss a proposed consent agreement.

By Emily Olsen • Jan. 26, 2026

Explore the Trendline➔

Drug pricing

President Trump’s efforts to install a most-favored nation pricing policy present new risks for an industry already adjusting to Medicare price negotiations.

By BioPharma Dive staff

Congress eyes tackling healthcare consolidation

“I think there’s common ground here,” one Republican congressman said Wednesday during a House Budget Committee hearing. Squaring up against healthcare monopolies would be a major pivot for the GOP.

By Rebecca Pifer Parduhn • Jan. 23, 2026

Trump unveils healthcare affordability plan

The “Great Healthcare Plan” is vague, but would send money directly to ACA enrollees and entrench the pricing deals the administration has cut with more than a dozen drugmakers.

By Rebecca Pifer Parduhn • Jan. 15, 2026

AbbVie pledges $100B to US production in drug pricing deal with Trump

As with the many other “most-favored-nation” deals between the White House and large pharmas, the agreement is short on details as well as its potential financial impact.

By Ben Fidler • Jan. 13, 2026

Biopharma climbs higher as 9 drugmakers ink ‘pandering’ drug price deals with Trump

Analysts see little effect on the bottom lines of biopharma companies, as they stand to stave off tariff pressure and receive other benefits from the agreements.

By Kristin Jensen • Dec. 22, 2025

UK agrees to boost drug prices to dodge US pharma tariffs

A deal announced Monday will see the U.K. temporarily sidestep levies on Britain-originated drugs by loosening rules that restrain prices for new medicines.

By Jonathan Gardner • Dec. 1, 2025

CMS sets 2027 Medicare prices for Wegovy, Trelegy and 13 other drugs

The second round of negotiations cuts spending an aggregate 44% over 2024 list prices as the federal government extends restraints over more medicines.

By Jonathan Gardner • Nov. 26, 2025

CMS to launch model to lower Medicaid drug spending

Under the model, set to start next year, the CMS will negotiate lower prices for Medicaid programs linked to those paid in select other countries.

By Emily Olsen • Nov. 7, 2025

Novo, Lilly cut deal with Trump to lower prices of obesity drugs

The agreement will make Wegovy and Zepbound available to some Medicare enrollees for $245 per month, and starter doses of pill versions, once approved, for $149 monthly.

By Jonathan Gardner • Updated Nov. 7, 2025

HRSA approves 340B rebate models to hospitals’ chagrin

Drugs that will be subject to rebates in 340B next year include Bristol Myers Squibb’s Eliquis, Johnson & Johnson’s Stelara and Novo Nordisk’s Novolog.

By Rebecca Pifer Parduhn • Oct. 31, 2025

FDA, aiming to lower drug costs, moves to speed approval of biosimilars

The agency will no longer require studies comparing copycat biologics to their branded counterparts, which could help developers bring them to market more quickly and cheaply. 

By Jonathan Gardner • Oct. 29, 2025

Lilly aligns with Walmart in bid to broaden access to discounted Zepbound

The deal, which enables patients to pick up orders placed through Lilly’s online channel at Walmart pharmacies, is the latest move by the company to expand its direct-to-consumer services. 

By Jonathan Gardner • Oct. 29, 2025

Novo’s main shareholder pushes out more than half of company’s board

The Novo Foundation chair said the current board of the Wegovy maker, which is already dealing with layoffs and a CEO change, was too slow to react to obesity market shifts.

By Jonathan Gardner • Oct. 21, 2025

California passes laws targeting PBMs, private equity

Gov. Gavin Newsom signed an array of healthcare bills into law last week that crack down on pharmacy benefit managers and beef up the review process for deals involving private equity firms.

By Susanna Vogel • Oct. 16, 2025

Trump, Pfizer drug pricing deal short on details, possible impact

A pact to offer “most favored nation” prices to state Medicaid programs and via direct-to-consumer channels doesn’t affect those on commercial insurance or who won’t pay out of pocket.

By Jonathan Gardner • Sept. 30, 2025

Key exemptions could limit impact of Trump’s pharmaceutical tariffs

Carve-outs for generics, European exports and companies onshoring drug production will likely shield most branded drugs from the 100% levies Trump announced Thursday.

By Jonathan Gardner • Sept. 26, 2025

Lilly says it will raise drug prices in Europe, responding to Trump threats

As the Trump administration works to implement a “most-favored nation” policy, Lilly said it’s “rebalancing” prices to “align” costs across different countries.

By Jonathan Gardner • Aug. 14, 2025

Regulatory uncertainty and access challenges changing go-to-market models, DTC, and DTP

DTC isn’t converting to Rxs at the pharmacy. Learn how access may be key to your brand’s success.

Aug. 11, 2025

Drugmakers score policy win in fight against 340B

A new pilot program from HHS will test alterations to the contentious 340B pricing program by swapping traditional upfront drug discounts for rebates.

By Amy Baxter • Aug. 4, 2025

Trump administration to pilot 340B rebate model next year

The pilot departs from the current model, which gives hospitals upfront discounts for some drugs. Hospitals say 340B is a lifeline, while drugmakers claim hospitals have abused the program.

By Susanna Vogel • Aug. 1, 2025

Trump redoubles threats in attempt to strongarm drugmakers on prices

The White House set a 60-day deadline for drugmakers to agree on “most favored nation” prices for Medicaid as well as for newly launched drugs.

By Jonathan Gardner • July 31, 2025

Apples to apples: Stelara biosimilars and the fight for market share

How will payers determine which Stelara biosimilar to add to their formularies?

By Samantha Ngan, Associate Manager, Market Research, MMIT and Andrew Rouff, Senior Consultant, Advisory Services, MMIT • July 21, 2025

Novartis CEO says resolution on Trump plan to cut US drug prices will take time

Conversations with the Trump administration on its “most favored nation” policy have been productive, the executive said Thursday. But the details, and their potential consequences, are still not clear.

By Ned Pagliarulo • Updated July 17, 2025

Congress should reconsider breaking up PBMs, experts say

Many proposals to reform the PBM industry miss the forest for the trees, experts said this week. Instead, Congress should go after the oligopoly enjoyed by the “Big Three” companies.

By Rebecca Pifer Parduhn • June 27, 2025